Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison center.

Published in: Clinical toxicology (Philadelphia, Pa.) (2018)

This study provides further evidence of both the safety and efficacy of physostigmine in the treatment of antimuscarinic delirium.

Keyphrases